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Abstract
In the blood coagulation cascade, Factor XIII (FXIII) is a zymogen that is activated by
thrombin (IIa) and Ca2+. Activated FXIII (FXIIIa) functions as a transglutaminase in the final
steps of the clotting cascade by forming covalent crosslinks between fibrin monomers at reactive
glutamine residues. This forms a stable clot structure, secure from proteolytic degradation. To
monitor FXIIIa substrate sequence specificity, the glutamine-containing peptide models S.
aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) were introduced to the enzyme in the
presence of 15NH4Cl. Using MALDI-TOF MS and 15N HSQC NMR experiments, it was seen
that α2AP(Q4P) (1-15) and K9 (1-10) were viable FXIIIa substrates, having isotopic nitrogen
incorporated in their side chain amide groups. However, S. aureus Fnb A (100-114) was not
able to undergo this catalytic reaction because of an interfering side reaction with the labeled
nitrogen. The substrate specificity appears to be the result of chemical environment provided by
the residues immediately surrounding the reactive glutamine, with a focus on the hybridization of
the side chain carbons. The αC(233-425) domain of fibrin monomers was also analyzed as an
intact FXIIIa substrate protein. The reactive Q328 residue of the protein was seen to undergo
enzymatic transglutamination linearly with time using MALDI-TOF MS. 2D 15N HSQC
experiments displayed that Q328 was not the only reactive glutamine in the protein but rather one
of two or three reactive glutamines.
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1. Introduction
Hemostasis is a vital physiological process that causes the cessation of blood loss from
wounded vessels of the circulatory system. Without this integral response to injury, the body
would not have the capability to quell bleeding while the vessel walls repair. In the dynamic
process of hemostasis, there are two basic mechanisms at work, vasoconstriction and blood
coagulation. The latter mechanism requires numerous enzymes working together to coordinate
the formation of a fibrin protein clot that stops blood flow. As seen in Figure 1, the coagulation
pathway is described as a cascade of regulated protein activations and may be initiated in two
possible pathways. The extrinsic pathway comes into play in the response to injury, whereas the

Intrinsic Pathway

Extrinsic Pathway

Figure 1: A schematic diagram of the
blood coagulation cascade. The major
point of emphasis is on the latter steps
which involve IIa, FXIII and
fibrinogen.
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intrinsic pathway is initiated upon appearance of blood outside of the circulatory system. The
two pathways later coalesce to a common enzymatic cascade that forms the fibrin clot.1
In the blood coagulation
cascade, the final steps of
clotting are achieved by
interactions among fibrinogen
(Fbg), thrombin (IIa) and
Factor XIII (FXIII). IIa is a
serine protease that cleaves Nterminal portions of fibrinogen
chains, releasing
Figure 2: Illustration of actions of IIa on fibrin monomers and the
aggregation of fibrin protofibers. Figure adapted from source.2

fibrinopeptides A and B (FpA
and FpB) and converting Fbg

(AαBβγ)2 into fibrin (αβγ)2 monomers. The fibrin monomers non-covalently associate into
protofibrils and then into fibers. This process is illustrated in Figure 2. The flexible αC
domains, residues 392-610, of the fibrin monomer are responsible for intermolecular interactions
that later facilitate the strengthening of the fibrin architecture.2 The structure of a fibrin
monomer and its αC domain may be seen in Figure 3. As a consequence of the increase in fibrin
concentration, the thrombin-mediated activation of FXIII is also enhanced. IIa, along with
increased Ca2+ concentrations, function to activate the FXIII for the next process in the clotting
cascade.3
In blood plasma, FXIII is found as a heterotetramer with an attached activation peptide.
There are two catalytic A-subunits and two inhibitory B-subunits; however, cellular FXIII is
found only as a dimer of two A-subunits. IIa initially facilitates the cleavage of the activation
4

peptide from the FXIII-A2,
and then the Ca2+ allows
the inhibitory FXIII-B2 to
dissociate. The calcium
ions are also needed to
bind at a Ca2+ binding site
near the catalytic core for
enzymatic activity. This
Figure 3: Illustration of the structure of a fibrinogen monomer,
including fibrinopeptides and αC domains. Figure modified from
source.2

process fully creates active
FXIII (FXIIIa) and can be

seen in Figure 4. FXIIIa initially crosslinks the γ-domains of the fibrin monomers. Then the
enzyme can function to covalently crosslink the fibrin monomers at their αC domains,
strengthening the clotting structure from proteolytic degradation.

Plasma

Figure 4: IIa and CaCl2
activation of plasma and
cellular FXIII.6

Cellular

Cellular FXIII (FXIIIc) is found as a dimer of A subunits (FXIII-A2) and is present in the
cytoplasm of macrophages and platelets. FXIIIc is activated in a similar manner as FXIIIp and
was the enzyme used in this study.2,4

FXIII may also be non-proteolytically activated by

concentrations of Ca2+ beyond physiological conditions, in excess of 10 mM.5
5

The crosslinking of fibrin monomers is achieved by FXIIIa’s transglutaminase activity,
which catalyzes an acyl transfer reaction between the side chain of a reactive glutamine (Q) and
the side chain of normally a

O
Protein1 - Gln

C

NH2

+

H2N Lys - Protein 2

NH3

Protein1 - Gln

C NH Lys - Protein 2
O

Figure 5: The transglutamination
between a glutamine and lysine
facilitated by FXIIIa. FXIIIa forms an
acyl enzyme intermediate, releasing
ammonia. The lysine then attacks the
intermediate and forms the isopeptide
bond.

lysine (K) residue.7 The γ-

carboxyamide of the glutamine residue serves as the acyl donor while the lysine residue
functions as the acyl acceptor. A Q-containing substrate is initially bound in the enzyme’s
catalytic thiol-containing site and is then followed by the nucleophilic attack of a K-containing
substrate’s sidechain amine. This creates the isopeptide bond between the two residues and
releases FXIII.7 A diagram of the transglutamination between glutamine and lysine may be seen
in Figure 5. A number of physiological substrates for FXIIIa have been identified; however, a
clear consensus sequence for the glutamine-containing substrate is not yet known.
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To analyze FXIIIa’s reactivity and substrate sequence specificity, varying peptide
models, approximately ten to fifteen residues in length, can be used. Because the exact source of
FXIIIa’s substrate specificity is not fully understood, the peptide sequences seen in Table 1 will
provide insight into how varying amino acid sequences affect enzymatic activity. Each peptide
model contains at least one reactive glutamine and has previously been shown to be an effective
FXIIIa substrate. Staphylococcus aureus (S. aureus) is a pathogenic bacterium that contains a
fibronectin binding protein A (Fnb A) that is able to be crosslinked into the human fibrin
network. The Fnb A therefore allows the S. aureus to anchor on to its host cell.7,8 Another
effective FXIIIa substrate is α2-antiplasmin (α2AP), a protein that prevents the activation of
Table 1: Glutamine-Containing FXIIIa Peptide Substrates and Q-containing αC regions
Substrate
Sequence (aligned by reactive Q)
100
SGDQRQVDLIPKKAT114
S. aureus Fnb A (100-114)
1
NQEQVSPLTLLKLGN15
α2AP (native) (1-15)
1
NQEPVSPLTLLKLGN15
α2AP(Q4P) (1-15)
1
LGPGQSKVIG10
K9 (1-10)
325
TGNQNPGSPRPGSTGTWNP342
αC(325-342)
363
STGQWHSESGSFRPDSPGSG382
αC(363-382)

plasmin from plasminogen. Plasmin is a protease that lyses existing clots. α2AP contains two
potentially reactive glutamines in residues 1-15 that target FXIIIa’s active binding site; however,
only Q2 participates in vivo. FXIIIa forms a crosslink between Q2 of α2AP and K303 of the
fibrin α-chain. An α2AP mutant, Q4P, also is used because of its substitution of the peptide’s
second glutamine for a proline. This mutation would allow the enzymatic role of the second
position glutamine to be probed. The peptide K9 (1-10) is also a peptide of interest, primarily
because it only contains one glutamine residue. The K9 peptide is based on the reactive site of a
larger FXIII substrate, β-casein.3
FXIIIa’s substrate reactivity can be successfully modeled with the above mentioned sample
peptides; however, to fully understand the scope of the enzyme’s natural function, intact proteins
7

and/or protein domains must also be studied. In previous work, it has been shown that the
fibrinogen αC region, residues 233-425, can interact and complex with FXIIIa, linking αC
glutamines and distant fibrinogen lysine residues. Therefore, the αC domains are major anchors
that hold the fibrin monomers together into a complex network.6 Also, recent studies suggest
that interactions with αC(233-425) may help promote FXIII activation. In the 192 residue αC
region, there are three glutamines that are potential targets of FXIII’s transglutaminase activity:
Q237, Q328 and Q366. The sequence of αC(233-425) ma14y be seen below, the glutamines in
red.2,3,6
233

TDMPQ237MRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWN
SGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSAGSWNSGSSGTGST
GNQ328NPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQ366WHSE
SGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGD
KELRT425
From various proteolytic digests of αC(233-425), distinct Q-containing fragments can be
generated, which allows for the observation of each glutamine’s reactivity by mass spectroscopy
methods. Previous work in this area had suggested that Q237 is not a primary enzymatic focus,
but the preference between Q328 and Q366 remained to be made.9 The sequences surrounding Q328
and Q366 can be seen in Table 1.
The reactive glutamines of the FXIII substrates may also be monitored by the use of the
enzymatically labeling technique (ELT). With ELT, isotopically labeled 15NH4Cl can act as a
lysine mimic and utilize FXIIIa’s transglutaminase activity to substitute the Q-NH2 on the
substrate with 15NH2. The FXIII still promotes the creation of an acyl intermediate with the
reactive glutamine, and without lysine, will undergo 15N exchange. This provides an invaluable
technique in determining the affinity and location of the reactive glutamine in various Qcontaining peptide sequences because the isotopically labeled residues can be readily detected by
15

N based-nuclear magnetic resonance (NMR) spectroscopy experiments.10 The ELT reaction
8

may be seen below in Figure 6. The isotopic labeling also allows the labeled nitrogen exchange
to be verified using matrix-assisted laser desorption ionization time of flight (MALDI-TOF)
mass spectroscopy. A shift in 1 m/z unit in the MS spectra of the FXIII-reacted peptides
indicates an isotopic exchange, a difference between 14N and 15N.3

Figure 6: Enzymatic labeling of the
γ-carboxyamide of reactive glutamine
using a 15N labeled ammonium
chloride.11

Another function of FXIIIa is its ability to facilitate the deamidation of a reactive glutamine
to a glutamic acid (E) in the absence of a lysine-containing substrate or mimic. Studies have
shown that when the substrate and enzyme are allowed to interact in an aqueous solution either
an isopeptide bond between two of the same peptides is produced or the aforementioned
deamidation reaction. The alteration of the Q to E can be monitored by a TOCSY (total
correlation spectroscopy) NMR experiment. By analyzing S. aureus FnbA(100-114) in solution
when it has and has not been introduced to FXIIIa should display two distinct spectra, one
containing a Q and one containing an E resonance pattern. In general, the deamidation produces
an upfield shift in the glutamine’s CαH, CβH and CγH protons’ chemical shifts. 3
Monitoring the ability of FXIIIa to carry out a transglutamination in response to varying
substrate sequences provides a better understanding of the enzyme’s substrate specificity. This
information would allow for a more detailed understanding of how FXIIIa forms covalent cross
links and how to manipulate them. Additionally, the interactions between FXIIIa and the αC
9

domains of fibrin(ogen) are of integral importance in the stabilization of the clot structure.
Understanding the preferential glutamine interactions between the two proteins would allow for
more control when engineering new methods of altering blood coagulation. The ability to more
specifically regulate the rate of formation and degradation of blood clots is a tool that would
prove useful and advantageous in all branches of healthcare and research.
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2. Specific Aims
The first aim of this research was to examine the substrate sequence specificity of FXIIIa
by determining the amino acid sequence that provides the greatest transglutaminase
reactivity from S. aureus FbnA, α2AP, α2AP(Q4P) and K9 peptide models.
a) FXIIIa’s transglutaminase activity was examined by the use of the enzymatic labeling
technique with 15NH4Cl. This allowed the glutamine amide protons of the peptide models to be
visualized using a 15N HSQC NMR experiment.
b) The isotopic reaction was further verified by monitoring the FXIIIa-mediated 15N exchange
via MALDI-TOF MS analysis. A shift of 1 mass unit was detected if the transglutamination was
successful.
The second aim of this research was to determine the reactivity of the three glutamine
residues in the αC region of fibrinogen towards FXIIIa.
a) In order to better monitor the enzyme’s transglutaminase activity, a lysine mimic, glycineethyl ester, was crosslinked to αC(233-425). This was developed into a timed kinetics assay.
b) The reacted peptide was then proteolytically digested with chymotrypsin to produce distinct
peptide fragments that allow the Q328 residue’s individual activity to be monitored. Using
MALDI-TOF MS, the rate with which the glycine ethyl ester is covalently crosslinked could be
observed.
c) FXIIIa was used to cross link αC(233-425) with another lysine mimic, dansylcadaverine (DC),
in a kinetics assay. Because DC fluoresces under UV light, the crosslinked αC+DC was isolated
with SDS-PAGE gel electrophoresis and verified by exposure to UV radiation.
d) FXIIIa’s transglutaminase activity was examined by the use of the enzymatic labeling
technique with 15N-labeled 15NH4Cl. This allowed the glutamine amide protons of the peptide
models to be visualized using a 1D and 2D 15N HSQC NMR experiment.
11

3. Experimental Procedures
3.1 Peptide Substrate Model Sequences and Sources, including FXIII
Peptide substrate models were synthesized and purified by New England Peptide,
Gardner, Massachusetts. Stock concentrations of the peptides were prepared in DI water. Their
individual concentrations were determined by quantitative amino acid analysis (AAA Services,
Boring, Oregon). The substrates analyzed include the following: S. aureus Fnb A (100-114),
α2AP (1-15), α2AP(Q4P) (1-15) and K9 (1-10). The peptides’ individual sequences may be seen
in Table 2. Human cellular FXIII (A2) was recombinantly expressed in Saccharomyces
cerevisiea and generously provided by Dr. Paul Bishop of ZymoGenetics Inc., Seattle,
Washington. Stock solutions of FXIII were prepared in DI water with their concentrations
determined using an extinction coefficient of E1%=14.9.
Table 2: Glutamine-Containing FXIIIa Peptide Substrates Models
Substrate
Sequence (aligned by reactive Q)
100
SGDQRQVDLIPKKAT114
S. aureus Fnb A (100-114)
1
NQEQVSPLTLLKLGN15
α2AP (native) (1-15)
1
NQEPVSPLTLLKLGN15
α2AP(Q4P) (1-15)
1
LGPGQSKVIG10
K9 (1-10)

3.2 Non-proteolytic Activation of FXIII and 15N Labeling of Peptide Substrate Models
The reaction was carried out in a 20mM borate buffer solution adjusted to pH 7. This
buffer condition supports FXIIIa activity and does not contribute any interfering protons during
NMR analysis. The reaction design took advantage of FXIIIa’s ability to be non-proteolytically
activated by elevated concentrations of Ca2+. 400nM of FXIII A2 was combined with 50mM of
CaCl2 in the borate buffer and allowed to incubate for approximately 15 minutes at 37°C in order
to non-proteolytically activate the enzyme. Afterwards, 100mM of 15NH4Cl was added along
with 200μM of substrate peptide, S. aureus Fnb A (100-114), α2AP (1-15), α2AP(Q4P) (1-15) or
K9 (1-10) in individual assays. The reaction mix was allowed to incubate for 30 minutes at room
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temperature before being prepared for analysis. For peptide samples in the absence of FXIIIa,
the initial addition and incubation steps with FXIII were omitted, and the remaining components,
borate buffer, CaCl2, 15NH4Cl and substrate peptides were combined. Comparing samples with
and without the addition of FXIII will examine if the enzymatic reaction took place with respect
to a nonenzymatically reacted control.
3.3 MALDI-TOF MS Analysis of 15N-labeled Peptide Substrate Models
The masses of the peptide substrates resulting from the FXIII and non-FXIII-mediated
reactions with 15NH4Cl were verified using an Applied Biosystems DE-Pro MALDI-TOF mass
spectrometer. The peptides were placed into UV absorbing matrix using 1.0μL aliquots of each
reaction sample mixed with 1.0μL of α-cyano-4-hydroxycinnamic acid (αCHCA) matrix
(5mg/mL αCHCA in a 1:1:1 ratio of 0.1% TFA, ethanol and acetonitrile).3 0.5μL of matrixsample mix were spotted in triplicate on a 100-well stainless steel MALDI plate and dried using
a speed-vacuum. The analysis was performed scanning the m/z range from 800 to 4000 Da with
the instrument in positive reflector mode.
3.4 Solution 15N HSQC NMR Studies
The 15N exchange seen by the peptide substrate models and αC(233-425) in the presence
of FXIIIa was analyzed using a 15N heteronuclear single quantum coherence (HSQC) NMRbased experiment. The short acquisition time for 1D HSQC experiments allows the reaction’s
progress to be measured as a function of time. The 400 μl NMR sample contained a 10% by
volume amount of D2O. This addition serves as an internal standard for the deuterium lock on
the NMR. NMR samples were loaded into Shigemi NMR tubes. Each experiment was
performed using an initial water suppression experiment. The parameters for each 1D 15N
HSQC experiment were nt=32, np=4096 and sw≈10,000. The parameters for each 2D 15N
HSQC experiment were nt=32, np=4096, sw=11,574, sw1=1944.3, bs=64, ni=8. The
13

parameters for each 2D TOCSY experiment were nt=32, np=4096, sw=7022.5, sw1=7022.5,
ni=256 and arrayed phasing. (nt= number of transients, np= number of points, sw=sweep width,
ni=number of increments) NMR experiments were performed on a Varian 700MHz
spectrometer equipped with z-axis pulse field gradients using a triple resonance probe. All
experiments were conducted at 25°C, with chemical shifts being referenced to the solvent, H2O.
3.4 αC Expression, Purification
The αC(233-425) protein was expressed using a glutathione-S-transferase (GST)-tagged
recombinant αC(233-425) plasmid DNA, generously provided by Dr. Helen Philippou and Dr.
Robert A.S. Ariëns from the University of Leeds. The protein was expressed using an
Escherichia coli BL21 Gold DE3 cell line in three separate 4 L cultures. IPTG was added to
each culture to initiate the expression of the αC protein of interest.The cultures were centrifuged,
allowing the E. coli cells to be isolated and washed. The cells were lysed open and a cell extract
was prepared. A protein-based solution was isolated from the cell extract. The αC(233-425) was
purified by using GST-affinity chromatography on an ÄKTAprime fast protein liquid
chromatography (FPLC) instrument. The affinity column contains resin beads that selectively
bind the GST, allowing the GST-protein to be isolated from the other biological compounds in
the cell-protein solution that elute off the column. The GST tag was removed from the αC(233425) with the use of a PreScission Protease digest while bound to the column, allowing the
protein of interest to be eluted in 1x phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM
KCl, 10mM Na2HPO4, 2 mM KH2PO4). The remaining cleaved GST was eluted off the column
with elution buffer containing 50 mM Tris-HCl, 20 mM reduced glutathione, 1mM DTT at pH
8.0. The purification method was modeled after the GE Healthcare recommended method,
which is where the protease and chromatography columns were purchased.9
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3.5 αC Crosslinking with Dansylcadaverine Observed by SDS-PAGE Analysis
The purity of the expressed αC(233-425)’s purity was assessed and confirmed by the use
of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). This method was
also used to verify that the molecular weight of αC(233-425) was within the estimated range.
The ability of the protein to be a FXIIIa substrate was assessed by enzymatically crosslinking the
αC protein’s reactive glutamines with a lysine mimic, dansylcadaverine (DC), which fluoresces
under UV light. This reaction is made possible by FXIIIa transglutaminase ability. 1.12 μM of
FXIII, 0.010μM IIa, 5 mM CaCl2 were combined in tris-acetate buffer (100 mM tris-acetate, 150
mM NaCl, 0.1% PEG8000, pH 7.4) and allowed to incubate for 15 minutes at 37°C to activate the
FXIII. Afterwards, 1.0 mM DC and 7.9 μM αC(233-425) were added which initiated the
reaction. Aliquots of the reaction mix were taken and quenched with a solution of 10% βmercaptoethanol and 2% SDS at times points of 0, 15, 30 and 45 minutes in order to monitor the
progress of the transglutamination. The reacted samples were then analyzed using SDS-PAGE
under non-reducing conditions. Samples were run on a 15% acrylamide gel, visualized under
UV light and then stained with Coomassie Blue.
3.6 αC Transglutamination with Glycine Ethyl Ester Assay
For this assay, the expressed αC(233-425) was enzymatically crosslinked with the lysinemimic, glycine ethyl ester (GEE). As before, the reaction was quenched at defined time points to
monitor the progression of the transglutamination. In tris-acetate buffer, 264 nM FXIII, 8.4 U/ml
IIa, 4mM CaCl2 and 17 mM GEE were combined and allowed to incubate for 10 minutes at
37°C. After the incubation period, the IIa was quenched with 164 nM PPACK, which is an
active site inhibitor of the enzyme. Following a brief incubation time with the PPACK, 17 μM
of the expressed αC was added to the reaction along with an additional 7 mM of CaCl2, to bring
the total CaCl2 concentration to 11 mM. Due to the phosphates present in the 1x PBS the αC
15

was eluted in, additional CaCl2 was added to account for the precipitation of the Ca2+ and the
phosphates. The resulting free Ca2+ concentration was then approximately 4 mM. This added
Ca2+ insures the continued activity of the FXIIIa. Reactions were quenched with a 10.6 mM
concentration of EDTA, a calcium ion scavenger.
3.7 αC Transglutamination with GEE Assay, Chymotrypsin Digest, and MS Analysis
After the αC(233-425)-GEE reaction samples were quenched with EDTA, they were
proteolytically digested with chymotrypsin which selectively cleaves αC after arginine and
lysine residues. A chymotrypsin digest is used because the αC protein is rather large to use for
MALDI-TOF MS analysis. The smaller protein fragments can be more accurately detected and
allow specific glutamines to be evaluated. Because the digest selectively produces a Q328containing fragment, the protease allowed the reaction at this reactive glutamine to be
specifically analyzed. Each digest took place in a volume of 13.1 μl, with 6 μl of the reaction
mix, 6 μl of chymotrypsin buffer (100 mM tris-HCl, 10 mM CaCl2, pH 7.4) and 1.1 μl of 25
mg/ml chymotrypsin in 1 mM HCl. The digest was allowed to proceed for 30 minutes and was
then followed by a quench with 6 μl of 5% TFA. After the quench, the samples were then
prepared for MALDI-TOF MS analysis. Because the excess salts can interfere with MALDI-MS
analysis, the digested samples were subjected to C18 zip tipping (Millipore) prior to being
combined with the αCHCA matrix and plated.
3.8 Non-proteolytic Activation of FXIII and 15N Labeling of αC(233-425)
The activation was carried out in a 20mM borate buffer solution adjusted to pH 7. FXIII
was nonenzymatically activated with elevated Ca2+ concentrations in this assay. 400nM of FXIII
was combined with 50mM of CaCl2 in the borate buffer and allowed to incubate for
approximately 15 minutes at 37°C. Afterwards, 100mM of 15NH4Cl and 10mM of additional
CaCl2, to account for phosphates, was added along with 20μM of αC(233-425) in 1x PBS. The
16

reaction mix was allowed to incubate for 45 minutes at room temperature before being prepared
to be analyzed. 1D and 2D 15N HSQC NMR experiments were conducted as with the peptide
substrate models.

17

4. Results
The substrate specificity of FXIIIa was analyzed with both peptide substrate models and the
intact αC(233-425) domain protein. The results from the different biochemical techniques
offered insights into the function and specificity of this integral protein in the blood coagulation
cascade.
4.1 MALDI-TOF MS Analysis of FXIIIa 15N-exchange with Substrate Peptide Models
This assay proved to be a valuable tool in evaluating the extent to which FXIIIa mediated
the isotopic 15N exchange at reactive glutamine residues of varying peptide sequences. The
difference in 1 mass unit (m/z) between the unlabeled (14N) and any enzymatically reacted (15N)
peptide would confirm that FXIIIa’s transglutaminase reaction had occurred. Three different
substrate peptides, S. aureus FnbA (100-114), α2AP(Q4P) (1-15) and K9 (1-10), were exposed to
15

NH4 in the presence and absence of FXIIIa. The isotopic labeling assay provided insight into

FXIIIa’s substrate sequence preference.

Figure 7: MALDI-TOF MS spectra of
substrate models exchanged with 15N in the
presence and absence of FXIIIa. The upper
panel of each pair displays the nonenzymatic
product, while the lower panels display the
enzymatically mediated products. Molecular
Weight: S. aureus FnbA(100-114): 1697
g/mol; α2APQ4P(1-15): 1622 g/mol; K9(110): 954.6 g/mol.
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The results of this experiment revealed the anticipated enzymatic behavior of FXIIIa on
α2AP(Q4P) (1-15) and K9 (1-10) substrates. The peptides appear in the MALDI-TOF spectra as
a cluster of peaks, or a centroid, which result from the natural isotopic abundances of the atoms
in the peptides. As seen in Figure 7, there is a clear shift in one peptide mass (m/z) unit when
comparing the mass centroids with and without the addition of FXIIIa. The interesting substrate
in this group was the S. Aureus FnbA (100-114); it displayed no mass shift. This absence
suggests that the expected amide exchange at the reactive Q residue was unsuccessful in both
catalytic and non-catalytic environments.
4.2

15

N HSQC NMR Analysis of FXIIIa 15N-exchange with Substrate Peptide Models
This 15N HSQC NMR based approach was used to monitor FXIIIa’s transglutaminase

activity on Q-containing substrate peptides. The 15N HSQC experiment selectively detects the
resonances of the protons on isotopically labeled nitrogens. Therefore, if the particular
resonances of two amide protons are detected in the experiment, it is evidence of 15N exchange.
Using a range of substrate sequences, other research groups have documented that the protons of
the 15N-labeled glutamine amides consistently resonate with the same chemical shifts and
peaking patterns, 6.9 and 7.5ppm as sharp singlets.10 However, these chemical shifts are not
static and do vary slightly between peptide sequences or if an intact protein such as αC is being
analyzed. A structure of the 15N-labeled glutamine may be seen in Figure 8.
From examining the spectra in Figure 9, it can
be seen that FXIIIa behaviors were not consistent
among the three different peptide sequences.
Beginning with K9(1-10), the FXIIIa-mediated
reaction displayed a very clear peaking pattern that

19

Figure 8: 15N-labeled glutamine at its
amide group.

other research groups have previously proven indicative of the enzymatically mediated isotopic
amide exchange. The resonances appeared at the anticipated frequencies and rendered two
sharp, separate peaks.10 In the absence of FXIIIa, there were no resonating protons in the
spectra, indicating that the 15NH4 was not exchanged at the reactive glutamine.

Figure 9: 1D 15N HSQC NMR spectra for region of interest (5.5-8ppm) in FXIIIa-mediated 15N-exchange of
substrate models. All samples includes 400μM peptide, 20mM borate buffer (pH 7), 50mM CaCl2, 100mM 15N
NH4Cl and varying by the addition or omission of 400nM FXIII. Samples were 10% D2O.

20

The next two substrates rendered more interesting results. The α2AP(Q4P) (1-15)
displayed the correct carboxyamide protons frequencies in the FXIIIa-mediated reaction, which
was expected. However, in the absence of FXIIIa, there was a new weak resonance in the region
between the observed locations of the two enzymatic peaks. The unexpected peak suggests that
there is a potential nonenzymatically mediated exchange between the peptide and the labeled
ammonium. It should be noted that this unexpected peak was distinct to the reaction without
FXIIIa and was not evident in the enzymatically reacted α2APQ4P sample’s spectrum. The S.
aureus FnbA(100-114) takes the unanticipated side reaction further by displaying the unknown
resonance at approximately 7
ppm in both the FXIIIa and non-

α2AP(Q4P) (1-14) +FXIII

FXIIIa-mediated reaction. The
peaking pattern not only
provides evidence of some
unanticipated interaction, but
also shows that this occurrence
hinders the ability of FXIIIa to

S. aureus Fnb A (100-114) +FXIII

catalyze the reaction. The
unanticipated peak at
approximately 7 ppm is the only
peak seen in the spectrum of the
enzymatic reaction. Neither of
Figure 10: 2D 15N HSQC NMR spectra of α2AP(Q4P) (1-14)
and S. aureus Fnb A (100-114) in the presence of FXIII.
Spectra were collected as previous work of Dr. Prakash
Doiphode.
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the sharp amide singlets is
observed, indicating that the

expected 15N-glutamine exchange had not taken place.
Previously generated 2D HSQC NMR spectra of α2AP(Q4P) (1-14) and S. aureus Fnb A
(100-114) in the presence of FXIIIa and 15NH4 were reviewed10. They may be seen in Figure 10.
The results showed a positive correlation to the results of the 1D spectra in Figure 9. The
α2AP(Q4P) peptide spectrum shows two strong peaks that resonate at approximately 6.5 and 7.3
ppm in the 1H dimension, which correlates to the chemical shifts observed in 1D resonances.
Also, the two peaks fall in a reasonable range in the 15N dimension to be classified as glutamine
side chain amide protons (110-115 ppm). Though not giving the clean amide peaks, the S.
aureus Fnb A peptide produced a similar peak in both 1D and 2D HSQC spectra. The large,
broad peak falls at the same 1H frequency in both 1D and 2D spectra. However, the 15N
frequency resonates at approximately 130 ppm, outside of the plausible glutamine side chain
amide range. The 15N must have incorporated into the peptide in a manner other than a
traditional transglutamination because the appearance of any resonance is indicative of 15N being
bonded to the peptide.
4.3 TOCSY NMR Analysis of FXIII Deamidation with Substrate Peptide Models
In the absence of a lysine mimic, FXIIIa can facilitate a deamidation of the reactive
glutamine to a glutamic acid. This chemical reaction can be monitored via a 2D TOCSY NMR
experiment. In order to have a base of comparison for the deamidation reactions, the chemical
shifts of the native Q-containing peptides first had to be identified. The TOCSY spectra of
native S. aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) were collected and analyzed.
The spectra of each peptide and assigned chemical shift table may be seen in Appendix A. Due
to complications in sample preparation of the FXIIIa-reacted peptides, the spectral quality was
greatly reduced which hindered the ability to fully assign all amino acid chemical shifts.
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Therefore, a visualization of the deamidation was not possible, but the assignment of the native
peptide spectra provides valuable information for future work.
4.4 SDS-PAGE Analysis of αC(233-425) Purification
The peptide substrates served as models to observe FXIIIa’s sequence specificity;
however, αC(233-425) allowed the enzyme’s activity to be observed in the presence of an intact
substrate protein. After being eluted as fractions off the GST-affinity column, the purity of the
expressed αC(233-425) was assessed by the use of SDS-PAGE. In Figure 11, the gradient
polyacrylamide gel stained with Coomassie Blue may be seen. The cellular protein solution
prior to being loaded on the GST-column was run in Lane 1. As expected, it contained
numerous proteins based on the many bands seen in the gel. The same observation can also be
made of Lanes 2 and 3. Lane 2 holds the eluent released while the protein solution was loaded
on the column. This eluent also contains many proteins because the only protein that is
selectively maintained on the column is the GST-tagged αC. Lane 3 contains the eluent from
washing the protein-bound column with PBS in order to remove any residual, extraneous
proteins. This wash is why the same band pattern is observed in Lane 3 as with the preceding
two lanes, because Lanes 1-3 all contain the same proteins, excluding αC. Lanes 4 and 5 both
contain separately eluted fractions of αC(233-425). Because of the presence of only one band in
each, this confirmed the fractions’ purities. Also, the bands in Lanes 4 and 5 ran level with the
molecular marker indicating 20 kDa, which is in expected mass range of the protein
(MW=19,500 Da).
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MW
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1

2

3

4

5

150 kDa

50 kDa

20 kDa

Figure 11: Gradient (4-20%) polyacrylamide gel stained with Coomassie Blue. Lane 1: Cell
solution before loaded on the column; Lane 2: the load eluent; Lane 3: wash eluent; Lanes 4
and 5: collected αC(233-425) fractions. αC(233-425) MW = 19,500 Da.

4.5 SDS-PAGE Analysis of αC(233-425) Crosslinking with DC
The reactivityMW
of αC(233-425) as a FXIIIa substrate was confirmed by the protein’s
Marker

ability to be crosslinked to the lysine-mimic, dansylcadaverine (DC). The structure of DC may
be seen in Figure 12. Activated via IIa and Ca2+, FXIIIa catalytically initiated the
transglutamination of the protein’s reactive glutamines with DC. When exposed to UV light, the
DC fluoresces which will allow the crosslinked αC+DC bands to be visualized. The gel of
crosslinked αC-DC exposed to UV light may be
seen in Figure 13. The band at 20 kDa can be
seen to fluoresce, indicating that the suspected
protein band observed in the eluted fractions was
αC.

Figure 12: Structure of the lysine-mimic,
dansylcadaverine. (DC)
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MW
Marker

αC(233-425) + DC Bands

20 kD

Figure 13: SDS-PAGE 4-20% gradient gel displaying crosslinked αC(223-425) (7.9μM) with
dansylcadaverine exposed to UV light. The four αC+DC bands are faint compared to the
marker, but are discernible.
4.6 MALDI-TOF MS Analysis of αC(233-425) Q328-GEE Crosslinking
To monitor the rate at which FXIIIa reacts with the targeted Q328 of αC(233-425), the
protein was crosslinked with the lysine-mimic, glycine ethyl ester. The structure of GEE may be
seen in Figure 14. Samples were allowed to react for discrete periods of time prior to a FXIIIa
quench. Glutamine 328 was selectively monitored via a chymotrypsin digest followed by
MALDI-TOF MS analysis. The digested fragment, αC(315-342), containing the reactive Q of
interest, exhibited a mass of 2448 m/z. As the reaction time was increased, the appearance of a
new fragment for GEE (86 m/z) crosslinked with the Q-containing αC(315-342) was observed.
From Figure 15, the MALDI-TOF MS spectra of the chymotrypsin digests at different FXIIIa
quench times may be seen, with the field zoomed to feature the Q-containing peak and the
GEE+Q328 peak. As the reaction time increased, the intensity of the crosslinked peak grew in
relative intensity while the Q-reactant’s peak diminished. There were some extraneous weak
peaks that appeared between the two peaks of interest.
These are contaminants and not sodiated or potassiated
peaks that need to be accounted.
To analyze the kinetic results in a more
quantitative manner, the changing concentration of the
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Figure 14: Structure of the lysine-mimic
glycine ethyl ester (GEE).

free Q328 peak was monitored. The consumption of the Q-reactant was monitored in each
spectrum by the following mathematical operation:
12

The results of the MALDI-TOF MS assay with respect to consumption of reactant can be seen in
Figure 16. From the regression of the data, it can be seen that FXIIIa’s transglutamination of
Q328 progressed in a linear fashion. However, it is very clear that Q328 was not completely
crosslinked with GEE because the free Q peak never goes away in Figure 15 and the
concentration of reactant only decreases by approximately 30 percent in Figure 16.

Figure 15: The MALDI-TOF MS spectra of the chymotrypsin digested αC(233-425) with varying times
of FXIIIIa transglutamination with glycine ethyl ester. Field of vision zoomed to feature the Q328containg fragment and Q328-fragment+GEE peaks. αC(315-342) sequence:
315
NSGSSGTGSTGNQNPGSPRGSTGTW342. Concentration of αC in the assay was 17μM.
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αC Q328 Kinetic Crosslinking
with GEE via FXIIIa
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Figure 16: Graph displaying the consumption of the αC Q328-containing reactant fragment over time.
The data is based on the MALDI-TOF MS data seen in Figure 13.

4.7

15

N HSQC NMR Analysis of FXIII 15N-exchange with αC(233-425)
Due to complications in concentrating the eluted αC(233-425) fractions, no stock protein

solutions could be generated with a concentration greater than approximately 30 μM. This low
concentration of stock solutions made it more complicated to prepare NMR samples that
contained enough αC(233-425) to be visualized in the experiment. However, one successful 2D
15

N HSQC NMR experiment was conducted on the protein in the presence of nonproteolytically

activated FXIIIa and 15NH4. The final protein concentration in the reaction sample was 20 μM,
which proved to be the minimal concentration of protein that could be visualized in an 15N
HSQC experiment. As in the isotopic transglutamination reactions that were conducted with the
peptide substrate models, FXIIIa can incorporate the labeled nitrogen at the glutamine side chain
amide so it may be visualized using 15N HSQC. The resulting 2D spectrum may be seen in
Figure 17. The αC(233-425) protein contains three glutamines, Q327, Q328 and Q366, with the
latter two being the residues of enzymatic focus.9 In the spectrum, two sets of glutamine chain
amide proton peaks are observed. A distinct pair of 15N-attached proton peaks may be seen at
(112.7, 7.55 ppm) and (112.7, 6.85 ppm) in the 15N and 1H dimensions, accounting for the
isotopic exchange at one glutamine. Another pair of peaks was observed at approximately 112.5
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ppm in the 15N dimension; however, this peaking pattern was not as well resolved in the 1H
dimension. One of the peaks in the pair was clear at 1H chemical shift of 6.8 ppm, while the
other peak was split into two separate 1H chemical shifts, 7.45 and 7.48 ppm. The newer
peaking pattern seen in the pair of peaks at 112.8 ppm in the 15N dimension may be related to the
chemical environment surrounding the second reactive Q or the contribution of a third glutamine
residue.

Figure 17: 2D 15N HSQC NMR spectra of αC(233-425) 20μM in the
presence of 15NH4Cl and nonproteolytically activated FXIII.
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5. Discussion
Blood coagulation is a dynamic process that involves a cascade of enzymatic activations and
reactions. The final stages of the clotting cascade revolve around the interactions among
thrombin (IIa), Factor XIII (FXIIII), calcium and fibrinogen which facilitate the ultimate
formation of a hard clot. IIa, a serine protease, cleaves fibrinogen into fibrin monomers and
removes the activation peptide from the FXIII. The increased Ca2+ concentration allows the
active FXIII-A2 subunit to dissociate from the inhibitory FXIII-B2 subunit and maintains the
enzyme’s activity during coagulation.2 Activated FXIII (FXIIIa) then facilitates the covalent
crosslinking between fibrin monomers, forming a hard blood clot. FXIIIa achieves this
crosslinking by its enzymatic ability to crosslink fibrin glutamines with normally fibrin lysine
residues. The αC domains of fibrin monomers are one of the key target sites for covalent
crosslinking by FXIIIa. However, FXIIIa does not uniformly react with glutamines found in
vivo. Only selected Q-containing sequences are actually targeted by FXIIIa transglutamination.3
The exact consensus sequence of FXIIIa’s enzymatic activity remains unknown, but with the use
of peptide substrate models and the αC(233-425) protein, a greater insight into the enzyme’s
selectivity may be deduced.
5.1 FXIIIa Interactions with Peptide Substrate Models
To monitor FXIIIa’s specificity towards a range of Q-containing amino acid sequences,
S. aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) peptide interactions with the
enzyme were studied. FXIIIa’s ability to exchange glutamine chain amides with 15NH4Cl, a
lysine mimic, provides a valuable isotopic labeling technique.10 The presence or absence of an
15

N-labeled glutamine after a FXIIIa-mediated reaction was used to evaluate the extent of

enzymatic transglutamination. Using 15N HSQC NMR and MALDI-TOF MS experiments, the
enzymatic reaction could be monitored for each peptide substrate model.
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By MALDI-TOF MS analysis, the exchange of the peptides’ Q-NH2 for 15NH2 would
appear as a shift of 1 m/z. From observing the results for each peptide, it was evident that not all
three peptides were successfully 15N-labeled by FXIIIa. In Figure 7, α2AP(Q4P) (1-15) and K9
(1-10) can be seen to display an upwards shift in 1 m/z unit in the FXIIIa-reacted spectra
compared to unlabeled controls. This indicates a successful transglutamination because of the 1
m/z difference between the two isotopes of nitrogen (14N and 15N). However, this shift in the
MALDI-TOF MS spectrum of S. aureus Fnb A(100-114) in the presence of FXIIIa and 15NH4
was not observed. This lack of change in m/z is why the spectrum of the unlabeled control is
identical to the spectrum of the enzymatically reacted S. aureus peptide. Therefore, the MALDITOF MS data suggest that only α2AP(Q4P) (1-15) and K9 (1-10) are capable of undergoing
enzymatic isotopic exchange via FXIIIa, while S. aureus Fnb A(100-114) is not.
In the 15N HSQC NMR studies, the change in m/z of isotopic labeling was not the aim.
Rather, the incorporation of an atom with spin=1/2, 15N, was the characteristic that was taken
advantage of in these experiments. In the 15N HSQC NMR experiment, only the proton attached
to nitrogen-15 can resonate. This indicates that an unlabeled protein should show no resonances
in its HSQC spectrum, while an 15N-labeled glutamine would produce two peaks for each 15Nattached proton.10
The 1D 15N HSQC spectra displayed in Figure 9, revealed that a range of peaking
patterns could be observed with the peptide substrate models. K9(1-10) presented the expected
outcome of the experiment. The unlabeled control showed no peaks, while the FXIIIa-reacted
sample showed the two sharp 15N-amide proton peaks as anticipated. Similarly, α2AP(Q4P) (115) showed the sharp twin peaks in the spectrum of the FXIII-reacted sample, but the unlabeled
control spectrum was not clear like that of K9 (1-10). In the nonenzymatically reacted sample,
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there appeared a weak, broad peak at approximately 7 ppm, which was an unexpected result.
This unexpected resonance in the nonenzymatically reacted α2AP(Q4P) (1-15) spectrum was
ruled out as an artifact when a similar unknown peak appeared in both of the spectra of S. aureus
Fnb A (110-114). In the absence of FXIIIa, the 15NH4 and S. aureus Fnb A peptide produced a
strong, broad resonance at approximately the same chemical shift of 7 ppm. The same unknown
peak was also seen in the spectrum of S. aureus Fnb A with the addition of FXIIIa. The
resonance in this spectrum is weaker than that of the one seen in the spectrum of the peptide
control, yet the peak is still very discernible in the spectrum.
By complementing the MALDI-TOF MS data with the results of the 15N HSQC NMR
results, a more encompassing picture can be formed about the substrate specificity of FXIIIa.
From the MALDI-TOF MS data, an answer to whether or not there was FXIIIa-facilitated
isotopic exchange at the reactive glutamine’s amide group could be deduced. The 15N HSQC
NMR experiments also provided this data; however, NMR also allowed for the examination of
any dynamic 15NH4-peptide interactions that do not result in a 1 m/z shift. This allowed FXIIIa
transglutaminase activity to be monitored and any enzymatically hindering processes to be
observed as well.
By reviewing the data in Figures 7 and 9, it can be seen that both methods agreed that the
three examined peptide models showed varying specificity towards FXIIIa. K9 (1-10) peptide
was a very effective substrate model in targeting FXIIIa’s enzymatic activity. Both NMR and
MS data show a lack of any 15NH4 interactions with K9 without the presence of FXIIIa, and both
confirm the isotopic exchange when the enzyme is present. This was the ideal situation expected
for any peptide that functions strongly as a FXIIIa substrate. α2AP(Q4P) (1-15) also was a
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successful target of FXIIIa’s activity. The appearance of two sharp NMR peaks and the 1 m/z
MS shift confirms α2AP(Q4P)’s ability to function as a FXIIIa substrate.
The peptide that proved to be the least effective FXIIIa substrate was S. aureus Fnb A
(100-114). There was no shift observed in the centroid of the MALDI-TOF MS spectrum nor
was there an appearance of the anticipated amide proton peaks in the HSQC spectrum.
Additionally, the NMR spectra of S. aureus Fnb A (100-114) displayed the peptide’s ability to
actively participate in an unknown isotopic interaction in both the presence and absence of
FXIIIa by the appearance of a broad peak at between 6.5 and 7 ppm. This resonance was
unexpected because any 15N HSQC NMR resonance, even a weak one, indicates that a labeled
nitrogen was incorporated into the peptide structure in some manner. However, this isotopic
addition must be distinct from a transglutamination for two reasons: there was no appearance of
the two sharp glutamine amide proton peaks in the HSQC spectrum nor was there a 1 m/z shift in
the MALDI-TOF MS spectrum. As seen in Figure 9, the S. aureus peptide participated in the
same nonenzymatic interaction that α2AP(Q4P) (1-15) had the propensity to do. However, S.
aureus Fnb A (100-114) showed a much higher affinity to participate in this unanticipated 15Nexchange in the absence of the enzyme than the α2AP(Q4P) peptide. The interaction with the
15

NH4Cl appeared to be so favorable that it out-competed FXIIIa attempts to carry out a

transglutamination reaction. This suggestion is based on the appearance of the same, yet more
diminished peak in the FXIIIa-containing S. aureus Fnb A (100-114) spectrum relative to the
nonenzymatic sample. Therefore, it can be seen that the unanticipated isotopic interaction
renders the peptide unable to undergo a FXIIIa-mediated reaction.
In order to provide further insight into the unexpected 1D HSQC peak seen between 6.5
and 7.0 ppm, 2D 15N HSQC NMR was utilized. Previously produced 2D HSQC spectra for the

32

FXIIIa-15NH4 reactions for both the S. aureus Fnb A and α2AP(Q4P) peptides were used to view
the 15N chemical shift of the peak.11 The 1D HSQC spectra chemical shifts are measured in the
1

H (ppm) dimension, while a 2D spectrum will allow resonances to be measured in both the 1H

and 15N (ppm) dimensions.
As seen in Figure 10, α2AP(Q4P) (1-15) displays two peaks that resonate with 1H
chemical shifts in the region of 7.5-6.5 ppm, the same frequencies as the sharp peaks seen in the
1D spectrum of the peptide in Figure 9. The chemical shift of the peaks in the 15N dimension is
also in the normal glutamine amide region, 110-115 ppm. The spectrum of the α2AP(Q4P)
peptide thus serves as a model 2D 15N HSQC spectrum of a successful FXIIIa 15N-labeled
glutamine. However, the spectrum of the S. aureus peptide displayed the same broad peak as in
the 1D spectrum, with the same 1H chemical shift, approximately between 7 and 6.5 ppm. The
peak in the 15N dimension had a chemical shift of approximately 131.5 ppm. This peak therefore
falls well out of the plausible range of glutamine side chain nitrogen protons, again verifying that
the isotopic interaction is distinct from the transglutamination facilitated by FXIIIa.
An explanation of this unanticipated peak must accommodate the experimental data that
has been found. The labeled nitrogen is incorporated into the S. aureus Fnb A (100-114)
structure by NMR analysis but there is no change in mass to charge ratio in the MS spectra. This
information would appear indicative of the 15N reacting with the peptide in a novel manner that
causes a proton to be lost while the isotope is bonded to the peptide. A reaction with these
results would explain why there was a signal in the 15N HSQC in the absence of FXIIIa and why
there was no observed shift the centroid of the MALDI-TOF spectrum. A potentially viable
reaction that would explain this data would be one involving the interactions among side chains
of the reactive glutamine (100SGDQRQVDLIPKKAT114), an arginine residue, and 15NH4Cl. The
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proposed mechanism for the reaction may be seen in Figure 18. The N-terminal serine residue’s
alcohol group could attack the δ-carbon of the glutamine side chain causing a tetrahedral
intermediate with an oxyanion (Step A). This unstable intermediate would allow the unlabeled,
H-bonded NH2 to leave as the carbonyl of glutamine reforms (Step B). The new serineglutamine intermediate then allows 15NH2 to be incorporated at the glutamine side chain (Step C).

E

B

Figure 18: Proposed mechanism for isotopic reaction observed in 15N HSQC experiments. The attacking
serine can be function intramolecularly or as a separate peptide residue. The general acid groups used in Steps
C and D could be serine or aspartate groups on the peptide or neighboring peptides.

This portion of the reaction manages the introduction of the 15N, while the next step involving
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arginine would account for the loss of the proton. Once the 15N is incorporated at the δ-carbon of
glutamine, instead of reforming the amide, an amidate group could form (Step D). This
structure places a double bond between 15N and C, causing a loss of one attached proton on the
labeled nitrogen. This step would explain the lack of a shift in m/z in the MS spectra following
the reaction. The oxyanion of the amidate form of glutamine could then be stabilized by
attacking the guanidinium carbon of the adjacent arginine (Step E). This final step would
stabilize the negatively charged oxygen and relieve the natural charge on the arginine group. The
proposed structure of the product can be seen in Step F of Figure 18.
This proposed structure would satisfy both the data that was presented in the 15N HSQC
NMR and MALDI-TOF MS results. Firstly, the labeled nitrogen in the structure could cause a
visible resonance with 15N HSQC analysis. The peaks 15N frequency being different from that of
normal glutamine amides can be explained by the change in nitrogen hybridization. In the native
glutamine, the nitrogen is sp3 hybridized, while in the proposed structure the 15N is sp2
hybridized. This could cause the nitrogen proton peak to resonate at a higher frequency in the
nitrogen dimension compared to glutamine chain amides, which was observed in Figure 10.
Secondly, the linking of the glutamine and arginine residues at the glutamine chain oxygen to the
guandinium carbon of arginine allows for the loss of a proton. This was a critical factor in
proposing the structure, because it must accommodate the lack of m/z shift seen in the MS data.
Additionally, the binding of the reactive Q to arginine could explain why FXIIIa was unable to
facilitate the anticipated transglutamination. α2AP(Q4P) may also be able to mildly undergo this
non enzymatic reaction in a similar fashion because of the appearance of a small broad peak at
approximately 7.0 ppm in the absence of FXIIIa. However, because of the absence of an
arginine residue, the mechanism would have to be distinct from the one proposed in Figure 18.
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A future method to verify this mechanism or provide further insight into the 15NH4Cl-mediated
reaction would be to conduct a tandem MS/MS mass spectrometry experiment. This strategy
would allow for observation of exactly which portion of the peptide has 15N incorporated and
consequently which residue(s) is causing the unanticipated side reaction.
Another FXIIIa quality that was to be taken advantage of in analyzing substrate
specificity was the enzyme’s ability to facilitate a deamidation of a glutamine to a glutamic acid
in the absence of a lysine mimic. This shift from a Q to E residue in the peptide structures could
be monitored by total correlation spectroscopy (TOCSY) NMR experiments. This NMR
experiment allows each proton of the amino acid chains to be assigned and monitored. The
deamidation reaction of FXIIIa would produce a spectrum distinct from a nonenzymatically
reacted peptide sample, based on the appearance of Q or E resonance patterns.3 As in 15N HSQC
NMR experiment, nonenzymatically reacted peptide samples were generated first as a basis of
comparison. The TOCSY spectra of the assigned amino acid residues of S. aureus Fnb A (100114) and α2AP(Q4P) (1-15) may be seen in Appendix A. In order to better visualize the proton
peaks, the pH of the samples were lowered to approximately pH 3.5. Unfortunately, various
concentration and pH complications arose during preparation of the FXIIIa-reacted peptide
samples. This resulted in spectra that displayed weak and unclear resonances. For this assay,
certain parameters need to be further optimized to aid in producing more resolved and useful
spectra. However, the native Q-containing TOCSY spectra of the S. aureus Fnb A and
α2AP(Q4P) peptides are reported in Appendix A because this was the first time these peptide
proton frequencies were assigned and the information can serve as a future tool in analyzing the
deamidation ability of FXIIIa.
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5.2 FXIIIa Interactions with αC(233-425)
To further evaluate the catalytic capabilities of FXIIIa, an intact substrate protein was
analyzed. The αC domain of fibrin monomers is the target of FXIIIa transglutamination that
causes the covalent crosslinking of the fibrin clot. The αC(233-425) region contains three
glutamines with two, Q328 and Q366, being potential targets to FXIIIa’s enzymatic activity.9 The
preference of FXIII to these two glutamine residues has yet to be clearly analyzed. Insights into
these interactions would provide a clearer view of FXIIIa’s substrate specificity.
The intact αC(233-425) protein was expressed and purified in multiple preparations in
order to provide stocks for FXIIIa enzymatic analysis. In order to verify the purity and ability of
the protein to be crosslinked by FXIIIa, SDS-PAGE was used. The clear, single bands seen in
the collected αC(233-425) fractions of Figure 11 show that the GST-affinity column successfully
isolated the protein. Additionally, when in the presence of the fluorescent lysine-mimic
dansylcadaverine, the αC(233-425) protein displayed FXIIIa transglutamination affinity, as seen
in Figure 13. The isolated αC protein bands of the SDS-PAGE gel were visualized under UV
light, indicating that the compound was incorporated into the protein by FXIIIa. This
information provided evidence that the expressed protein was in fact αC(233-425), based on
molecular weight and substrate sequence specificity towards FXIIIa.
The MALDI-TOF MS assay designed to observe FXIIIa’s ability to crosslink the lysinemimic glycine ethyl ester to Q328 of αC(233-425) provided information on the catalytic reaction.
Using a chymotrypsin digest, the Q328-containing fragment was isolated. From Figure 15, it can
seen that in the MALDI-TOF MS spectra of the FXIIIa-facilitated reaction, a GEE+Q328fragment peak appeared over time. When this information was quantified with respect to the loss
of the Q328 fragment over time, a linear dependency was observed. However, from Figure 16, it
can be seen that the slope of the graph, i.e. reaction velocity, was not as large as would be
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expected with an enzymatic reaction. This observation could be a result of the low concentration
of protein that was used in the assay. Because of issues with concentrating αC(233-425), the
assay had to be conducted using lower than desired concentrations of protein. This low substrate
concentration could have not met FXIIIa’s Km value, which would have slowed the progression
of the enzyme’s functions. Also, continuing work in this study would include conducting the
assay again at various αC(233-425) concentrations in order to collect each distinct slope or
reaction velocity. With the reaction velocities over a range of substrate concentrations, a
Lineweaver-Burk plot could be generated to render more enzyme kinetic data.
Further studies based on this MALDI-TOF-based assay would also try to monitor the
enzymatic activity at Q366. A different proteolytic digest from chymotrypsin must be used in
order to isolate a Q366. This data would provide a basis of comparison between the two reactive
glutamines. Additionally, αC(233-425) mutants could be expressed to even further selectively
monitor the catalytic reaction at each glutamine. The first mutant of focus would be Q237N,
Q366N. This new protein would only allow the Q328 residue to be susceptible to
transglutamination by FXIIIa.
The intact αC(233-425) was also introduced to the 15NH4Cl in the presence of FXIIIa to
allow the protein to be isotopically labeled. The 15N is incorporated into the reactive glutamine
side chain amide groups, allowing them to be specifically monitored using 15N HSQC NMR. In
the 2D HSQC spectrum of the enzymatic reaction seen in Figure 17, there appear to be two sets
of glutamine amide proton peaks. However, one of the pairs of peaks was not seen as the
expected two, clear resonances. One of the peaks appears as two small peaks, rather than one
larger one. This could potentially be explained by the Q237 residue, which previously was not
seen to greatly participate in crosslinking. The two strong sets of peaks would likely be the
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resonances of the amide protons of the reactive Q328 and Q366, with the one extra peak being
caused by mild Q237 activities. Future studies would be aimed at labeling the specific glutamine
peaks in the 15N HSQC spectra in order to selectively monitor the enzymatic reaction at the
residue of interest. Also, the αC(233-425) could be expressed with 15N initially incorporated into
the structure of the glutamines’ side chain amides. In the presence of unlabeled NH4Cl, FXIIIa
would facilitate the removal of the isotopic nitrogen. This reaction could be monitored using a
similar 15N HSQC experiment in a time dependent fashion.
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6. Conclusion
From the experimental data, FXIIIa displayed varying substrate specificity towards the
various model peptides. K9 (1-10) and α2AP(Q4) (1-15) proved to be viable substrates of the
enzymatic transglutamination reaction, with K9 showing the greatest affinity. The S. aureus Fnb
A (100-114) peptide favored undergoing a distinct isotopic reaction with 15NH4, rather than the
anticipated FXIIIa reaction. This newly proposed interaction between reactive glutamine and
neighboring arginine residues of the peptide and the small lysine mimic appeared to be so
favorable that no enzymatic activity was observed in the presence of FXIIIa. The cause of this
substrate sequence specificity seems to come from the residues that are directly adjacent to the
reactive glutamine. The S. aureus Fnb A and α2AP(Q4P) peptides both have residues containing
sp2 hybridized side chain carbons in arginine and glutamate, respectively, besides the reactive
glutamine. This hybridization quality could allow an environment for the oxyanion of the
amidate to be stabilized, as in the proposed mechanism. The arginine residue of S. aureus Fnb A
(100-114) appears to undergo this reaction with greater ease than the glutamate of α2AP(Q4P)
(1-15), as the latter peptide functioned as a FXIIIa substrate. In contrast, K9 (1-10) has its
reactive glutamine flanked by glycine and serine residues, both of which only have sp3
hybridized side chain carbons. This environment appears to not favor the nonenzymatic isotopic
exchange, allowing for greater FXIIIa activity.
Additionally, the intact αC(233-425) protein was seen to be a target of FXIIIa’s
transglutaminase activity. Q328 was observed to react with the enzyme in a linear fashion with
time; however, because of low protein concentrations beneath the Km value of FXIIIa, the
maximum velocity could not be reached. αC(233-425) was able to undergo transglutamination
at multiple glutamine residues, two and potentially three. This work has provided insights into
40

the function and sequence specificity of FXIIIa and therefore, further information that can
contribute to the manipulation of the blood coagulation cascade.
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8. Appendix A

Figure A.1: Structure of S. aureus
Fnb A (110-114) with labeled amino
acids. pH 7
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8. Appendix A

Figure A.1: Structure of S. aureus
Fnb A (110-114) with labeled amino
Figureacids.
A.2: 2D TOCSY expansion of the aliphatic region of S. aureus FnbA (110-114) (100SGDQRQVDLIPKKAT114).

Figure A.3: 2D TOCSY expansion of the fingerprint region of S. aureus Fnb A (110-114) (100SGDQRQVDLIPKKAT114).
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Figure A.4: 2D TOCSY expansion of the amide backbone region of S. aureus Fnb A (100-114) (100SGDQRQVDLIPKKAT114).
Chemical Shift (ppm)
residue
S100
G101
D102
Q103
R104
Q105
V106
D107
L108
I109
P110
K111
K112
A113
T114

NH
8.357
8.552
8.4
8.384
8.29
8.384
8.125
8.267
8.141
8.033
n/a
8.368
8.32
8.068
8.46

α

CH
4.424
3.955
n/a
4.29
4.252
4.29
4.055
n/a
4.304
4.414
4.36
4.252
4.29
4.256
4.377

CβH

Others

3.859
n/a
2.78, 2.669
1.97, 2.077
1.828, 1.771
1.97, 2.12
2.058
2.769, 2.696
1.57
1.838
2.264, 2.032
1.785, 1.728
1.795, 1.728
1.182
n/a

n/a
n/a
n/a
γ 2.341
γ 1.618, δ 2.992
γ 2.341
γ 0.8992
n/a
δ 0.8932, 0.8048
γ .09231, 0.8704
γ 1.965, 1.866; δ 3.881, 3.66
γ 1.445, δ 1.675 , ε 2.992
γ 1.445, δ 1.675 , ε 2.992
n/a
γ 1.394

Table A.1: Summary of chemical shift assignments in ppm for S. aureus Fnb A(110-114). Experiments were
performed at 25˚C. Samples were buffered in 20 mM borate at pH 7.0, 50 mM CaCl2, 100 mM 15NH4, 10% D2O.
Peptide concentration was 200μM.
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Figure A.5: Structure of α2AP(Q4P)
(1-15) with labeled amino acids. pH 7

46

Figure A.6: 2D TOCSY expansion of the aliphatic region of α2AP(Q4P) (1-14) (1NQEPVSPLTLLKLGN15).

Figure A.7: 2D TOCSY expansion of the fingerprint region of α2AP(Q4P) (1-14) (1NQEPVSPLTLLKLGN15).
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Figure A.8: 2D TOCSY expansion of the amide backbone region of α2AP(Q4P) (1-14) (1NQEPVSPLTLLKLGN15).
Chemical Shift (ppm)
α

β

residue
NH
CH
CH
Others
N1
8.303 n/a
2.815, 2.73
n/a
Q2
8.489 n/a
2.096, 1.893
γ 2.494
E3
8.747 4.404 2.079, 1.978
γ 2.35
P4
n/a
4.396 2.318, 2.091
γ 1.934; δ 3.87, 3.788
V5
8.24
4.083 2.012
γ 0.9381
S6
8.443 n/a
3.889
n/a
P7
n/a
4.396 2.267, 2.012
γ 1.871; δ 3.774, 3.680
L8
7.989 4.294 1.657, 1.564
n/a
T9
7.914 4.193 n/a
γ 1.2
L10
7.989 4.294 1.657, 1.564
n/a
L11
7.974 4.269 1.657, 1.564
n/a
K12
8.151 4.277 1.834, 1.741
γ 1.414, 1.365; δ 1.805, 1.756; ε 2.965
L13
7.957 4.269 1.657, 1.564
n/a
G14
8.344 3.922 n/a
n/a
N15
8.285 n/a
2.815, 2.73
n/a
Table A.2: Summary of chemical shift assignments for α2AP(Q4P) (1-14). Experiments were performed at 25˚C. Samples
buffered in 20 mM borate at pH 3.5, 50 mM CaCl2, 100 mM 15NH4, 10% D2O. Peptide concentration was 200μM.
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